Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804381 | 0.87 | SLC6A2 (0.32) | HTR3A | |
| SCHEMBL20758368 | 0.87 | CCR5 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4HTR3A | |
| SCHEMBL397520 | 0.87 | SLC6A2 (0.32) | HTR3A | |
| SCHEMBL29217207 | 0.87 | SLC6A2 (0.32) | HTR3A | |
| SCHEMBL4852595 | 0.87 | SLC6A2 (0.32) | HTR3A | |
| SCHEMBL4806245 | 0.87 | SLC6A2 (0.32) | HTR3A | |
| SCHEMBL16042628 | 0.85 | — | — | |
| SCHEMBL16992087 | 0.77 | L3MBTL1 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL1810152 | 0.76 | MAPT (0.36) | KDM4EALDH1A1 | |
| SCHEMBL9410053 | 0.76 | MAPT (0.36) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4385988-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-115703765-A | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| WO-2019035008-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2019-02-21 | — | — | WO | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230419-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC7, BIRC3 | CHRNB2 4583/4885CHRNB4 4454/4885CHRNA3 4697/4885 |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GABRA5, SLC6A11, GABRA1 | CHRNB2 683/4885CHRNB4 542/4885CHRNA3 438/4885 |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | CDK4, CDK6, CDK1 | CHRNB2 4124/4885CHRNB4 3669/4885CHRNA3 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.